WHAT IS CLAIMED IS:

1. A method of treating moderate to severe glabellar lines (GL) and/or lateral canthal lines (LCL) in a human subject, comprising administering a therapeutically effective amount of a liquid composition comprising a botulinum neurotoxin to the subject, thereby reducing the appearance of moderate to severe GL and/or LCL, wherein the liquid composition further comprises 1-5 buffering agents, at least one stabilizer, and at least one surfactant.

2. The method of claim 1, where the liquid composition comprises at least 4 buffering agents.

3. The method of claim 1 or 2, wherein the liquid composition comprises a first buffering agent present at a concentration of about 100 to about 300 mM, or at a concentration of about 0.1-10 mg/mL.

4. The method of claim 3, wherein the liquid composition comprises a second buffering agent present at a concentration of about 1 to about 25 mM, or at a concentration of about 0.1-1.0 mg/mL.

5. The method of claim 4, wherein the liquid composition comprises a third buffering agent present at a concentration of about 1 to about 25 mM, or at a concentration of about 0.1-1.0 mg/mL.

6. The method of claim 5, wherein the liquid composition comprises a fourth buffering agent present at a concentration of about 1 to about 25 mM, or at a concentration of about 0.1-1.0 mg/mL.

7. The method of claim 6, wherein the liquid composition comprises a fifth buffering agent present at a concentration of about 1 to about 25 mM, or at a concentration of about 0.1-1.0 mg/mL.

8. The method of any one of claims 1-7, wherein the buffering agents are selected from the group consisting of sodium chloride, potassium chloride, sodium phosphate, potassium phosphate, di-sodium hydrogen phosphate dehydrate, and sodium dihydrogen phosphate dehydrate.

9. The method of any one of claims 1-8, wherein the at least one stabilizer is an amino acid.

10. The method of claim 9, wherein the amino acid is selected from the group consisting of alanine, valine, leucine, isoleucine, methionine, phenylalanine, tyrosine, and tryptophan.

11. The method of claim 9 or 10, wherein the amino acid is in the D isoform or the L isoform.

12. The method of any one of claims 9-11, wherein the amino acid is present at a concentration of about 0.1 to about 3.0 mg/mL.

13. The method of any one of claims 1-12, wherein the at least one surfactant is a non-ionic surfactant.

14. The method of claim 13, wherein the non-ionic surfactant is present at a concentration of about 0.01% (v/v) to about 5.0% (v/v), or at a concentration of about 0.1 to about 3.0 mg/mL.

15. The method of any one of claims 1-14, wherein the botulinum neurotoxin is selected from the group consisting of botulinum neurotoxin types A, B, C, D, E, F and G.

16. The method of claim 15, wherein the botulinum neurotoxin is botulinum neurotoxin type A.

17. The method of any one of claims 1-16, wherein the pH of the liquid composition is between 6.6 and 6.9.

18. The method of any one of claims 1-17, wherein the botulinum neurotoxin has a molecular weight of about 150 kDa.

19. The method of any one of claims 1-18, wherein the osmolality of the liquid composition is between 270 mosm/kg and 310 mosm/kg.

20. The method of any one of claims 1-19, wherein between 1 and 100 units of botulinum toxin is administered to the subject.

21. The method of claim 20, wherein between 10 and 75 units of botulinum toxin is administered to the subject.

22. The method of claim 20, wherein between 25 and 75 units of botulinum toxin is administered to the subject.

23. The method of claim 20, wherein 10, 25, 30, 45, 50, 60, 75, or 90 units of botulinum toxin is administered to the subject.

24. The method of any one of claims 1-23, wherein the liquid composition is administered by injection.

25. The method of claim 24, wherein the injection is subdermal, transdermal, intradermal or intramuscular.

26. The method of claim 24 or 25, wherein the subject is injected multiple times in the glabellar region.

27. The method of claim 26, wherein adjacent injections are separated by about 0.5 to about 10 cm.

28. The method of claim 26, wherein adjacent injections are separated by about 1.5 to about 3 cm.

29. The method of any one of claims 26-28, wherein the injections are in the procerus muscle and the corrugator supercillii muscles on each side of the face.

30. The method of claim 29, wherein the injections are first made in the procerus muscle followed by the corrugator supercillii muscles on each side of the face, moving outwards from the median.

31. The method of any one of claims 26-30, wherein all the injections are about 1 cm above the upper orbital rim and internal to the mid-pupillary lines.

32. The method of any one of claims 26-31, wherein all the injections are at least 1 cm above the central eyebrow or the bony supraorbital ridge.

33. The method of any one of claims 26-32, further comprising applying pressure on the upper orbital rim while injecting to minimize risks of regional effect of the botulinum neurotoxin.

34. The method of claim 26 or 27, wherein the subject is injected multiple times below the lateral canthus, in the external part of the orbicularis oculi, and/or 1-2 cm from the orbital rim.

35. The method of any one of claims 26-33, wherein the subject is further injected multiple times below the lateral canthus, in the external part of the orbicularis oculi, and/or 1-2 cm from the orbital rim.

36. The method of any one of claims 1-35, wherein said method is repeated at intervals from about 1 month to about 6 months to inhibit said recurrence.

37. The method of claim 36, wherein said method is repeated at intervals from about 3 months to about 6 months to inhibit said recurrence.

38. The method of claim 36, wherein said method is repeated at intervals of about 4 months to inhibit said recurrence.

39. A liquid composition comprising a botulinum neurotoxin and 1-5 buffering agents, at least one stabilizer, and at least one surfactant for use in treating glabellar lines and/or lateral canthal lines in a subject.

40. Use of a liquid composition comprising a botulinum neurotoxin and 1-5 buffering agents, at least one stabilizer, and at least one surfactant for treating glabellar lines and/or lateral canthal lines comprising administering the liquid composition to a subject in need thereof.